Dupilumab Approved for Chronic Spontaneous Urticaria

The US Food and Drug Administration (FDA) has approved dupilumab for the treatment of chronic spontaneous urticaria (CSU) in patients aged 12 years and older who “remain symptomatic despite H1 antihistamine treatment,” according to a press release from the manufacturers, Regeneron Pharmaceuticals and Sanofi.  Approval follows the FDA’s request in October 2023 for more efficacy …